Created in 2005 with an endowment from the late Portuguese entrepreneur, António Champalimaud, the Champalimaud Foundation is dedicated to harnessing novel methodologies to make advances in biomedical science. The majority of the Foundation’s activities are housed at the state-of-the-art Champalimaud Centre for the Unknown (CCU). Based in a historic riverside area in Lisbon, this facility contains the most advanced conditions for clinical care, research, technological innovation and teaching.
Within the CCU, the Champalimaud Clinical Centre (CCC) is a state-of-the-art medical facility for management of oncologic, neuropsychiatric and related diseases. Its core mission is the provision of premier patient management supported by programmes of translational research. Facilities for consultation, diagnosis and state-of-the-art treatment are available at this unique location.
In the four years since first opening its doors the CCC has grown rapidly in a focused expansion designed to offer comprehensive and world-leading prevention, diagnosis and treatment of disease. In 2014 the CCC offered over 35,000 medical consultations, 30,000 imaging appointments, 14,000 radiotherapy sessions, over 1000 surgeries, and 8,000 chemotherapy sessions. Annual growth in patients treated has exceeded 100% year-on-year since operations began.
The Champalimaud Foundation is committed to advancing scientific research through its Champalimaud Research structure. This cutting-edge research platform focuses on neuroscience, cancer and associated cancer biology, while seeking synergies, collaboration and translation across all areas. In 2012 the Champalimaud Centre for the Unknown was named in the scientific press as the best place in the world, outside the USA, to conduct post-doctoral research.